Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy.
Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy.
复制标题
DOI：
10.3988/jcn.2009.5.1.1
复制
发表时间：
2009-03
期刊：
影响因子：
--
通讯作者：
Park HJ
中科院分区：
文献类型：
--
作者：
Lee PH;Park HJ
帕金森病（PD）和多系统萎缩（MSA）是以富含α-突触核蛋白的路易小体和胶质细胞质包涵体为病理特征的α-突触核蛋白病的神经退行性疾病代表。胚胎干细胞、胎儿中脑神经元和神经干细胞已被引入PD动物和患者的恢复策略，但伦理和免疫学问题以及肿瘤发生和致残性运动障碍的严重副作用限制了这些干细胞的临床应用。同时，利用间充质干细胞（MSCs）进行细胞治疗在临床上很有吸引力，因为这些细胞没有伦理和免疫学问题。MSCs存在于成人骨髓中，占所有有核骨髓细胞的0.01%。间充质干细胞本身具有多能性，在适当条件下可分化为软骨细胞、骨骼肌细胞和神经元。根据最近的研究，MSCs的神经保护作用是通过其产生各种有助于功能恢复、神经元细胞存活和刺激内源性再生的营养因子的能力和免疫调节特性介导的，这些特性不仅抑制几乎所有参与免疫反应的细胞-细胞接触依赖机制，而且还释放各种与免疫抑制活性相关的可溶性因子。然而，在PD和MSA中使用MSCs作为神经保护剂的研究很少。在这里，我们全面回顾了MSCs在PD和MSA中的治疗作用的最新进展，特别是关注它们的神经保护特性和在疾病改善治疗策略中的应用。
Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases representative of α-synucleinopathies characterized pathologically by α-synuclein-abundant Lewy bodies and glial cytoplasmic inclusions, respectively. Embryonic stem cells, fetal mesencephalic neurons, and neural stem cells have been introduced as restorative strategies in PD animals and patients, but ethical and immunological problems as well as the serious side effects of tumorigenesis and disabling dyskinesia have limited clinical application of these stem cells. Meanwhile, cell therapy using mesenchymal stem cells (MSCs) is attractive clinically because these cells are free from ethical and immunological problems. MSCs are present in adult bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are themselves capable of multipotency, differentiating under appropriate conditions into chondrocytes, skeletal myocytes, and neurons. According to recent studies, the neuroprotective effect of MSCs is mediated by their ability to produce various trophic factors that contribute to functional recovery, neuronal cell survival, and stimulation of endogenous regeneration and by immunoregulatory properties that not only inhibit nearly all cells participating in the immune response cell-cell-contact-dependent mechanism, but also release various soluble factors associated with immunosuppressive activity. However, the use of MSCs as neuroprotectives in PD and MSA has seldom been studied. Here we comprehensively review recent advances in the therapeutic roles of MSCs in PD and MSA, especially focusing on their neuroprotective properties and use in disease-modifying therapeutic strategies.
登录
查看更多内容
影响因子：
5.1
作者：
Guo, Jun;Lin, Guo-sheng;Hu, Ming-yan
通讯作者：
Hu, Ming-yan
影响因子：
8.6
作者：
Adler, CH
通讯作者：
Adler, CH
影响因子：
11.2
作者：
Bove, Jordi;Zhou, Chun;Przedborski, Serge
通讯作者：
Przedborski, Serge
影响因子：
5.3
作者：
Gao, HM;Hong, JS;Liu, B
通讯作者：
Liu, B
影响因子：
4.7
作者：
Aubin, N;Curet, O;Carter, C
通讯作者：
Carter, C